|Daily Range||$33.18 - $33.43|
|52-Week Range||$31.50 - $38.54|
|Dividend (Yield)||$0.00 (2.5%)|
|Average Daily Volume||1,215,756|
|Current FY EPS||$1.82|
Positive new data for a promising new treatment for brain cancer could help clear the way to a new standard of care.
Last week's most exciting healthcare news: Exelixis nets a win, and Colorado takes aim at health insurers.
If you have some extra cash and want to take a chance, these six stocks have the potential for excellent returns.
With five compounds unchallenged in their class, Roche has one of the industry's most exciting late-stage pipelines.
Financial results trump the FDA approval of a key new drug.
An increase in spending caused results to come up a bit short of expectations, but the long term story appears to be on track.
Our Motley Fool contributors think that these 3 biotech stocks are great buys right now.
Our contributors think that healthcare-focused investors should watch these 5 long-term healthcare trends.
The sequencer maker scales the wall of worry created by its competitor.
Roche's once-failed rheumatoid arthritis therapy hit a bullseye in relapsing multiple sclerosis.